Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D; VX09-809-102 study group. Boyle MP, et al. Among authors: rodman d. Lancet Respir Med. 2014 Jul;2(7):527-38. doi: 10.1016/S2213-2600(14)70132-8. Epub 2014 Jun 24. Lancet Respir Med. 2014. PMID: 24973281 Clinical Trial.
A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.
Konstan MW, Döring G, Heltshe SL, Lands LC, Hilliard KA, Koker P, Bhattacharya S, Staab A, Hamilton A; Investigators and Coordinators of BI Trial 543.45. Konstan MW, et al. J Cyst Fibros. 2014 Mar;13(2):148-55. doi: 10.1016/j.jcf.2013.12.009. Epub 2014 Jan 17. J Cyst Fibros. 2014. PMID: 24440167 Free PMC article. Clinical Trial.
Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.
Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B, Hamblett N, Heald AE. Moss RB, et al. Among authors: rodman d. Chest. 2004 Feb;125(2):509-21. doi: 10.1378/chest.125.2.509. Chest. 2004. PMID: 14769732 Clinical Trial.
Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study.
Noone PG, Hamblett N, Accurso F, Aitken ML, Boyle M, Dovey M, Gibson R, Johnson C, Kellerman D, Konstan MW, Milgram L, Mundahl J, Retsch-Bogort G, Rodman D, Williams-Warren J, Wilmott RW, Zeitlin P, Ramsey B; Cystic Fibrosis Therapeutics Development Research Group. Noone PG, et al. Among authors: rodman d. Pediatr Pulmonol. 2001 Aug;32(2):122-8. doi: 10.1002/ppul.1098. Pediatr Pulmonol. 2001. PMID: 11477729 Clinical Trial.
Late diagnosis defines a unique population of long-term survivors of cystic fibrosis.
Rodman DM, Polis JM, Heltshe SL, Sontag MK, Chacon C, Rodman RV, Brayshaw SJ, Huitt GA, Iseman MD, Saavedra MT, Taussig LM, Wagener JS, Accurso FJ, Nick JA. Rodman DM, et al. Among authors: rodman rv. Am J Respir Crit Care Med. 2005 Mar 15;171(6):621-6. doi: 10.1164/rccm.200403-404OC. Epub 2004 Dec 10. Am J Respir Crit Care Med. 2005. PMID: 15591474
Circulating RNA transcripts identify therapeutic response in cystic fibrosis lung disease.
Saavedra MT, Hughes GJ, Sanders LA, Carr M, Rodman DM, Coldren CD, Geraci MW, Sagel SD, Accurso FJ, West J, Nick JA. Saavedra MT, et al. Among authors: rodman dm. Am J Respir Crit Care Med. 2008 Nov 1;178(9):929-38. doi: 10.1164/rccm.200803-387OC. Epub 2008 Aug 21. Am J Respir Crit Care Med. 2008. PMID: 18723435 Free PMC article.
Cystic fibrosis critical care: no longer an oxymoron.
Wallick K, Nick JA, Rodman DM. Wallick K, et al. Among authors: rodman dm. Am J Respir Crit Care Med. 2001 Feb;163(2):310-2. doi: 10.1164/ajrccm.163.2.ed2000d. Am J Respir Crit Care Med. 2001. PMID: 11246640 No abstract available.
125 results